|
On-line Registrations closed. Walk-in Registrations will be open on site. "Opportunities for Entrepreneurs in the Life Sciences." The TIE Institute, in Collaboration with the Special Interest Groups, will be launching a series of seminars of broad interest to TIE members, titled "Opportunities for Entrepreneurs". Our goal is to give TIE members exposure to technology developments in Massachusetts that create opportunities for entrepreneurs, with the expectation that interactions between leading-edge scientists and engineers on the one hand and entrepreneurs on the other will create new businesses, which is TIE's over-arching goal. The first of these, co-sponsored by the Life Sciences and Health Care SIG, will be Opportunities for Entrepreneurs in the Life Sciences, on 6 December 2007.
This seminar will feature Haleh Armian and Beverly Brown of the Center for Integration of Medicine and Innovative Technology (CIMIT) and Brock Reeve of the Harvard Stem Cell Institute (HSCI). They will describe the work that is being done in their organizations, illustrated with specific examples. They will also suggest ways to learn more about what they do and ways to interact with their scientists and engineers.
About CIMIT CIMIT fosters and nurtures interdisciplinary collaboration among world-class experts in medicine, science and engineering, in concert with industry and government, to rapidly improve patient care. A non-profit consortium of Boston area teaching hospitals and engineering schools, CIMIT provides innovators with resources to explore, develop and implement novel technological solutions for today’s most urgent healthcare problems. See www.cimit.org.
About HSCI The HSCI is currently focused on basic research and clinical translation in five principal disease areas: cancer , diabetes, nervous system diseases (such as ALS and Parkinson's), blood diseases (including AIDS), and cardiovascular disease. These diseases are among the early priorities for HSCI, but our mission is broader and encompasses basic research on all aspects of stem cell biology, with special emphasis on areas where there is a potential opportunity to improve human health. In the United States alone it has been estimated that as many as 100 million people suffer from diseases that could be amenable to stem cell-based therapies. We want to take advantage of these opportunities to the fullest extent possible. Accordingly, faculty working groups have been established in disease areas in addition to those listed above, including muscle, kidney, skin, the reproductive system, liver and gastrointestinal tract, and tissue engineering. See www.hsci.harvard.edu.
Register early, for space is limited, and the seminar will sell out. Speakers include
Haleh Armian, Senior Business Development Manager, Center for the Integration of Medicine and Innovative Technology (CIMIT), plus others from CIMIT (www.cimit.org/)
|
